C4 Therapeutics (NASDAQ: CCCC) files 8-K on Q3 2025 results press release

Rhea-AI Filing Summary

C4 Therapeutics, Inc. furnished a press release announcing its financial results and business highlights for the quarter ended September 30, 2025.

The press release, dated November 6, 2025, is included as Exhibit 99.1 to this Form 8-K and is treated as furnished rather than filed under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001662579false00016625792025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________

FORM 8-K

_________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

_________________________________________________________________

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________________

Delaware			001-39567			47-5617627
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
490 Arsenal Way,   Suite 120 Watertown,  MA						02472
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 231-0700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CCCC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, C4 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number						Description
99.1						Press release issued November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			C4 Therapeutics, Inc.
Date: November 6, 2025			By:			/s/ Jolie M. Siegel
						Jolie M. Siegel
						Chief Legal Officer and Secretary

FAQ

What did C4 Therapeutics (CCCC) disclose in this Form 8-K?

C4 Therapeutics disclosed that it issued a press release announcing financial results and business highlights for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K filed on November 6, 2025.

Which period’s results are covered in C4 Therapeutics (CCCC) latest update?

The update covers C4 Therapeutics’ financial results and business highlights for the quarter ended September 30, 2025. Details of those results are contained in the press release attached as Exhibit 99.1 to the Form 8-K filed on November 6, 2025.

How is the C4 Therapeutics (CCCC) press release treated under SEC rules?

The press release attached as Exhibit 99.1 is intended to be furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is only incorporated by reference if specifically stated in another filing.

Which exhibits accompany the C4 Therapeutics (CCCC) Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release issued November 6, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document. These exhibits support the company’s current report disclosure.

Who signed the C4 Therapeutics (CCCC) Form 8-K report?

The Form 8-K was signed on behalf of C4 Therapeutics, Inc. by Jolie M. Siegel, who serves as Chief Legal Officer and Secretary. The signature is dated November 6, 2025, reflecting authorization of the current report’s submission.